204 related articles for article (PubMed ID: 31009931)
1. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
2. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
5. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
[TBL] [Abstract][Full Text] [Related]
6. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
7. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.
Spadaro M; Montarolo F; Perga S; Martire S; Brescia F; Malucchi S; Bertolotto A
Clin Immunol; 2017 Aug; 181():83-88. PubMed ID: 28642148
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
[TBL] [Abstract][Full Text] [Related]
12. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F
Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169
[TBL] [Abstract][Full Text] [Related]
13. Disability progression
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Mechanisms of Action of Glatiramer Acetate.
Prod'homme T; Zamvil SS
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
[TBL] [Abstract][Full Text] [Related]
15. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.
Rieks M; Hoffmann V; Aktas O; Juschka M; Spitzer I; Brune N; Schimrigk S; Przuntek H; Pöhlau D
Eur Neurol; 2003; 50(4):200-6. PubMed ID: 14634263
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.
Weber MS; Hohlfeld R; Zamvil SS
Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
